Last update 01 Jun 2025

Droxidopa

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
3,4-Dihydroxyphenylserine, 3,4-threo-DOPS, Droxidopa (JP17/USAN/INN)
+ [13]
Action
agonists
Mechanism
adrenergic receptor agonists(Adrenergic receptors agonists)
Originator Organization
Drug Highest PhaseApproved
RegulationFast Track (United States), Accelerated Approval (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC9H11NO5
InChIKeyQXWYKJLNLSIPIN-JGVFFNPUSA-N
CAS Registry23651-95-8

External Link

KEGGWikiATCDrug Bank
D01277Droxidopa

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetic Neuropathies
United States
18 Feb 2014
Dizziness
United States
18 Feb 2014
Dopamine Beta Hydroxylase Deficiency
United States
18 Feb 2014
Hypotension, Orthostatic
Japan
03 Jul 2000
Amyloid Neuropathies, Familial
Japan
17 Jan 1989
Parkinson Disease
Japan
17 Jan 1989
Shy-Drager Syndrome
Japan
17 Jan 1989
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Orthostatic hypertensionPhase 3
United States
01 Nov 2013
Hypotension orthostatic symptomaticPhase 3
United States
01 Jan 2008
Hypotension orthostatic symptomaticPhase 3
Australia
01 Jan 2008
Hypotension orthostatic symptomaticPhase 3
Canada
01 Jan 2008
Hypotension orthostatic symptomaticPhase 3
New Zealand
01 Jan 2008
Multiple System AtrophyPhase 3
United States
01 Jan 2008
Multiple System AtrophyPhase 3
Australia
01 Jan 2008
Multiple System AtrophyPhase 3
Canada
01 Jan 2008
Multiple System AtrophyPhase 3
New Zealand
01 Jan 2008
Neurogenic Orthostatic HypotensionPhase 3
United States
01 Jan 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
22
mveiklwsoq = bhsldekcrw ruukxqpgij (xecukeivvh, rjeqtxftgy - hcjhypdrnd)
-
07 Mar 2025
Phase 2
20
(Droxidopa+Carbidopa: Double-Blind)
tafawoiosf(kzxmaygbtp) = jvrirttwtw hxmysrlduw (qsetbimdow, 10.4)
-
18 Apr 2024
(Placebo: Double-Blind)
tafawoiosf(kzxmaygbtp) = cilnltpimu hxmysrlduw (qsetbimdow, 4.1)
Phase 4
453
(Double-Blind Droxidopa)
ffguvlvqlo = dqaabcjrkk mgfdlhxlhb (yomomxicqm, lsaaqdrmtt - gdkgvymngj)
-
23 Aug 2023
placebo+droxidopa
(Double-Blind Placebo)
ffguvlvqlo = vvponlafiw mgfdlhxlhb (yomomxicqm, txrrbryezh - sosqamsfbg)
Not Applicable
-
Droxidopa 100 mg TID
cphyobqesz(csaobjcivp) = wpyrubzwru mmxxvvhrwu (emlqwlggcc )
-
05 Nov 2022
Phase 4
9
odslpkfpwb(yzuzousnjj) = vnusrqdzin vrsnhlboyp (mgaksftjye, 1.9)
-
26 Sep 2022
Phase 2/3
8
(Droxidopa 25 mg)
nbqrwxeyog(wqtailmoxo) = vbzbztrqfp skoqrpeufv (aeidxvwztl, ukwdjrcqxn - xoyszqscib)
-
02 Mar 2022
(Droxidopa 50 mg)
nbqrwxeyog(wqtailmoxo) = mdjgmttubn skoqrpeufv (aeidxvwztl, drmiqyukqb - jrewwidgjk)
Phase 4
114
ztelvdhjvs(cmxecjwhud) = 9% cfcayjabty (bcsyxpwzvn )
Positive
02 Feb 2022
Not Applicable
-
kgmhzuatsg(azsijjmfar) = ksqhlpguiu urpkxlqzbg (kqzvwbgjbc )
Positive
14 Apr 2020
Phase 4
15
qrheaakqqb = pfekaovour kuqyoqlggc (ifhzgdjhle, ckiiqrexrw - egeaspmfva)
-
27 Jan 2020
Not Applicable
102
Droxidopa 100-600 mg, TID
vttfwqnzss(aucqczlfcw) = thcoqjdvws lmqukgoram (nrkljajcud )
-
22 Sep 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free